

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) RLL-319US In Re Application Of: GHANDI et al. Application No. Filing Date Examiner Customer No. Group Art Unit Confirmation No. 10/538,354 26815 Unknown Unknown COATING COMPOSITION FOR TASTE MASKING COATING AND METHODS FOR THEIR APPLICATION Title: AND USE Address to: **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) 1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: ☐ the statement specified in 37 CFR 1.97(e); OR $\Box$ the fee set forth in 37 CFR 1.17(p).

## TRANSMITTAL OF INFOR TION DISCLOSURE STATEMEN Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) RLL-319US GHANDI et al. In Re Application of: Group Art Unit Confirmation No. Customer No. Application No. Filing Date Examiner 26815 Unknown 10/538,354 Unknown COATING COMPOSITION FOR TASTE MASKING COATING AND METHODS FOR THEIR APPLICATION Title: AND USE Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. 50-0912 The Director is hereby authorized to charge and credit Deposit Account No. as described below. Charge the amount of Credit any overpayment. Charge any additional fee required. ☐ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Mailing by First Class Mail Certificate of Transmission by Facsimile\* I hereby certify that this correspondence is being deposited I certify that this document and authorization to charge deposit with the United States Postal Service with sufficient postage account is being facsimile transmitted to the United States as first class mail in an envelope addressed to Patent and Trademark Office (Fa "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on 11312006 (Date) Signature of Person-Mailing Correspondence Michelle Morgan Typed or Printed Name of Person Mailing Certificate Typed or Printed Name of Person Signing Certificate \*This certificate may only be used if paying by deposit account. Dated: January 3, 2006 William D. Hare Reg. No. 44,739 **CUSTOMER NO. 26815**

CC:



## **INFORMATION DISCLOSURE CITATION**

Docket No.: RLL-3 Serial No.: 10/538,354

Applicants: GANDHI et al.

Filed: 6/13/2005

Group:

			U.S. P	ATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	6,106,861	8/22/2000	Chauveau <i>et al.</i>	424	465	
	A2	6,136,347	10/24/2000	Pöllinger et al.	424	495	
			FOREIGN	I PATENT DOCUMEN	тѕ		
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO
	B1,	WO 98/14179	4/9/1998	PCT	A61K	9/50	
	B2	WO 99/44581	9/10/1999	PCT	A61K	9/00	
,	B3	WO 03/026615	4/3/2003	PCT	A61K	9/00	
	,						
		OTHER DOCUME	NTS (Includ	ding Author, Title, Date,	Pertinent Pa	ages, Etc.)	
	C1	BASF Corporation, "Specification for 'Kollicoat IR', Product Number 55554797", retreived from the internet - http://www.basf.com/pharma					
	C2	Pachione, "FCE Pharma. Lançamentos Desafiam Câmbio Volátil", Revista Química e Derivados, Online No. 408 (2002), retreived from the internet - http://www.quimica.com.br/revista/qd408/fce1.htm					
	C3	Pharmacopoeial Forum, <u>23(4)</u> :4388-4392 (1997)					

EXAM	NER	DATE CONSIDERED
		· · · · · · · · · · · · · · · · · · ·

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.